Alnylam Pharmaceuticals and Sanofi’s Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance

Goodwin advised Alnylam Pharmaceuticals, Inc. on its strategic restructuring of its RNAi therapeutics alliance with Sanofi to streamline and optimize development and commercialization of certain products...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Jiangsu Hengrui Medicine and TG Therapeutics’ Global License Agreement for Development and Commercialization of Novel BTK Inhibitor Program

Goodwin advised Jiangsu Hengrui Medicine as it entered into an exclusive global license agreement with TG Therapeutics. Under the terms of the agreement, Jiangsu Hengrui will...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here